



The Green Organic Dutchman Holdings Ltd.

Management's Discussion and Analysis

For the three months ended March 31, 2021 and March 31, 2020

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis ("MD&A") reports on the interim consolidated financial condition and operating results of The Green Organic Dutchman Holdings Ltd. (the "Company" or "TGDH") for the three months ended March 31, 2021 and 2020. The MD&A should be read in conjunction with the Company's interim condensed consolidated financial statements for the three months ended March 31, 2021 and March 31, 2020 (the "Interim Consolidated Financial Statements") which were prepared in accordance with International Accounting Standards ("IAS") 34, International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). This MD&A provides information on the operating activities, performance and financial position of the Company and is intended to assist in understanding the Company's business and key factors underlying its financial results. **All dollar amounts referred to in this MD&A are expressed in thousands of Canadian dollars except where indicated otherwise.**

Additional information relating to the Company can be found on the Company's website at www.tgod.ca or at the Company's SEDAR profile at www.sedar.com.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This MD&A may contain "forward-looking information" ("FLI") within the meaning of Canadian securities legislation ("forward-looking statements"). These forward-looking statements are made as of the date of this MD&A and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities laws. Forward-looking statements relate to future events or future performance and reflect Company management's expectations or beliefs regarding future events.

In some cases, these forward-looking statements can be identified by words or phrases such as "may", "might", "will", "expect", "anticipate", "estimate", "intend", "plan", "indicate", "seek", "believe", "predict" or "likely", or the negative of these terms, or other similar expressions intended to identify forward-looking statements. The Company has based these forward-looking statements on its current expectations and projections about future events and financial trends that it believes might affect its financial condition, results of operations, business strategy and financial needs. Some examples of forward-looking statements include but are not limited to the expected costs, completion dates of the facilities, production capacity, receipt of licences, etc.

Assumptions

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate and are subject to risks and uncertainties. In making the forward-looking statements included in this MD&A, the Company has made various material assumptions, including but not limited to:

- (i) the availability of financing at all or on reasonable terms;
- (ii) the Company's ability to continue as a going concern and successfully execute its plans and intentions, including with respect to the construction and operation of the Company's cultivation facilities and generation of revenues and sales of its organic cannabis products;
- (iii) eventual completion of the construction and/or the sale of the Company's facility in Québec;
- (iv) obtaining necessary regulatory approvals;
- (v) general business and economic conditions, particularly in the Canadian medicinal and adult-use cannabis markets;
- (vi) regulation of the markets in which the Company operates;
- (vii) the Company's ability to attract and retain skilled staff;
- (viii) market competition, including the products and technology offered by the Company's competitors;
- (ix) maintenance of our current good relationships with our suppliers, service providers and other third parties; and
- (x) ability to continue to operate during the implementation of COVID-19 restrictions and maintaining necessary access and safety protocols.

Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There is no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. We do not undertake to update or revise any forward-looking statements, except as, and to the extent required by, applicable securities laws in Canada. The Company's forward-looking statements are based on the reasonable beliefs, expectations, and opinions of management as of May 12, 2021, the date of this MD&A.

BUSINESS OVERVIEW

The Company was incorporated under the Canada Business Corporations Act on November 16, 2016. The Company's registered and head office is located at 6205 Airport Rd., Building A – Suite 200, Mississauga, Ontario L4V 1E3. The Company completed its initial public offering on May 2, 2018. The Company's common shares ("Common Shares") trade on the TSX under the symbol "TGOD" and on the OTCQX under the symbol "TGODF". The Company also had four classes of warrants listed on the TSX under the symbols "TGOD.WS", "TGOD.WR", "TGOD.WA" and "TGOD.WB".

The Company's wholly-owned subsidiaries, The Green Organic Dutchman Ltd. and Medican Organic Inc., are licensed producers under the Cannabis Act (Canada) and hold licences to produce cannabis plants, cannabis plant seeds, dried cannabis, fresh cannabis, cannabis oils, cannabis topicals, cannabis extracts and edible cannabis and, with respect to The Green Organic Dutchman Ltd. only, to process and sell such cannabis products within Canada to provincially authorized retailers and distributors as well as certain federally licensed entities. The Company owns and operates a cannabis cultivation and processing facility in Hamilton, Ontario (the "**Hamilton Facility**"). The Company also owns another facility located in Valleyfield, Québec (the "**Quebec Facility**") which is being held for sale within the next twelve months and a monetization review is under way.

In addition to its Canadian operations, through its subsidiaries and strategic investments, the Company is pursuing an international growth strategy, including through a hemp extraction business based in Poland. The Company has also established other strategic partnerships for the distribution of cannabis and hemp-derived medical products in Mexico, Germany, and other countries as regulations allow.

The outbreak of the novel strain of the coronavirus, SARS-COV-2 ("COVID-19"), and its eventual declaration as a pandemic by the World Health Organization ("WHO") on March 11, 2020 has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures have caused material disruption to businesses globally resulting in an economic slowdown. The Company rapidly implemented strategic measures to protect its global workforce from COVID-19 and endeavouring to mitigate any long-term impact of the pandemic on its business. While it is difficult to predict the impact of COVID-19 on the Company's business, the Company continues to seek to mitigate these impacts through various means including engagement with its retailers, transition of its staff to working remotely where possible, increasing safety protocols and sanitation measures within the workplace, and monitoring developments in order to adapt and respond in order to protect the health and safety of the Company's employees and the best interests of the Company.

Since inception, the Company has incurred recurring operating losses, having invested significantly in its cultivation facilities, research and development activities and selling, marketing, general and administrative expenses. The Company has financed its operations through equity and debt financings. The Company expects to continue to incur losses from operations in the short term and will require additional capital and revenues through the sale of its organic cannabis products to fulfill its debt obligations. Please refer to the section on "Liquidity and Capital Resources" below.

RECENT DEVELOPMENTS AND BUSINESS OBJECTIVES

Executive Leadership

On March 9, 2021, the Company announced that its board of directors has appointed Sean Bovingdon as CEO, member of the board, and interim CFO, effective immediately.

Quebec Facility Updates

On February 19, 2021, the Company announced that it was seeking to monetize under-utilized assets at its Quebec Facility and had retained the services of a commercial real estate advisor to identify potential buyers for assets located at this site, focused on the state-of-the-art hybrid main greenhouse. The transaction could result in a complete or partial sale of the assets located at this site. Management notes that the Canadian cannabis industry has gone through a deep transformation with the approval of outdoor cultivation sites – approximately 450 acres of land were used for outdoor cannabis cultivation in 2020. This shift disrupted the business plans of many licensed producers, including the Company, and resulted in biomass surpluses. Based on management's current market forecasts, the Company's main greenhouse and other assets located at its Quebec Facility could be monetized to allow the Company to continue its path to right sizing and profitable operations. Expected export opportunities are addressable with existing production capacity, while the option to purchase cannabis biomass from other producers for extraction, including in Quebec, offers a more efficient use of capital. The Company remains committed to maintaining a significant portion of its operations, including all 2.0 product manufacturing, in Quebec, either at a portion of the Quebec Facility or at an alternative Quebec site. Although highly probable, there can be no assurances that the Quebec Facility will ultimately be monetized either by way of a sale or any other form of transaction.

On April 29, 2021, the Company provided an update to the transaction stating that it had received multiple viable bids. Management and its advisors are currently working through the details of the bids and anticipates progressing towards signing a definitive purchase and sale agreement and closing by the end of June 2021. Many of the offers received include the ability for the Company to lease back the small portion of the Quebec Facility that is currently in use, such that the Company anticipates minimal disruption to current operations and no requirement for the Company to expend capital for any relocation.

Medical Cannabis by Shoppers™ (“Shoppers”) Supply Agreement

On February 1, 2021, the Company unveiled plans to transition its medical business to a wholesale model, in line with other pharmaceutical products' distribution models. The Company's patient-centered approach will enable easier access to a broad range of medical cannabis products without having to register with multiple licensed producers. Shoppers Drug Mart Inc. represents Canada's largest pharmacy network and the Company is its largest supplier of organically grown medical cannabis. Every effort has been made to ensure that there is no supply disruption for patients and all of the Company's products will be available via Shoppers' online store platform. The Company also has agreements with other medical distributors and clinics, with plans to increase its presence within the medical market as it transitions from its legacy direct-to-patient model. The Company supported its patients throughout the transition period which was completed April 1st, 2021.

Launch of Stillwater's Ripple Brands in Canada

On January 28, 2021, the Company announce the launch of *RIPPLE Gummies by TGOD* (“RIPPLE Gummies”), the first cannabis-infused confectionary product to offer a scientifically validated 15-minute onset. RIPPLE Gummies are initially available in Alberta, British Columbia, and Manitoba, with plans to expand distribution across the country once provincial listings are received. RIPPLE Gummies are made using certified organically grown cannabis, real fruit juice and all-natural flavours and colours. Each pack contains two precisely dosed 5mg THC-gummies for a total of 10mg, the maximum allowed under Canada's *Cannabis Act*. RIPPLE Gummies leverage the same fast-acting proprietary technology used in quick-dissolving RIPPLE powder. As part of its licensing agreement with Stillwater, the Company plans to further expand its RIPPLE offering with additional flavours Honey Infusion CBD and Mango Balance, scheduled to launch in the second quarter of 2021.

New Products and Distribution in 2021

On January 18, 2021, the Company announced the launch of Amsterdam Sativa under its mainstream brand, Highly Dutch. Offered in three different formats, 3.5g, 15g, and 28g, Amsterdam Sativa is now available in Alberta, Saskatchewan, Manitoba, Ontario, Quebec and Newfoundland. Amsterdam Sativa has a high potency with a THC level of 17% – 20%. It is organically grown and expertly cured in order to maintain a balanced humidity level to protect the integrity of its terpenes and trichomes. The buds included in Amsterdam Sativa are carefully selected to deliver a consistent potency and quality in every batch. The first product launched under the Highly Dutch brand was Rotterdam Indica, a similarly high-THC flower, which is also available in Alberta, Saskatchewan, Manitoba, Ontario, Quebec and Newfoundland. As at the date of this MD&A, Highly Dutch added Organic Afghan Black, a high-quality hash, to its line of products, which is now available in British Columbia, Alberta, Manitoba, Quebec and Newfoundland, with plans to further expand distribution across other provinces.

On February 11, 2021, the Company announced that it has signed a supply agreement with CannMart, a subsidiary of Namaste Technologies Inc., making its certified organic medical cannabis products available via CannMart's online medical cannabis sales platform. Under the Company's two-year term agreement with CannMart, the Company will provide CannMart with a broad portfolio of certified organic medical cannabis products, including premium dried flower, RIPPLE dissolvable powder, gummies, and teas.

On February 18, 2021, the Company announced the addition of Organic Sugar Bush to its portfolio of premium strains. The Company's Organic Sugar Bush, a high-THC Sativa variety, was developed based on feedback from consumers and presents a THC level higher than 20%, large buds, certified organically grown, and balanced humidity to preserve its terpenes and trichomes. Organic Sugar Bush gets its name from Quebec's maple forests – the Company's grow team analysed a myriad of strains before selecting Organic Sugar Bush, a strain it perfected by developing a unique cultivation method which includes the addition of maple syrup from Quebec to its proprietary living soil. The launch of Organic Sugar Bush is the continuation of the Company's plans to introduce innovative strains as part of its premium portfolio. In fact, all TGOD's main premium organic strains (Organic LA Con, Organic Rockstar Tuna, Organic Fire, as well as Organic Sugar Bush) are being consistently harvested now with potencies greater than 20% THC. On April 29, 2021, the Company announced that it continues to work on expanding distribution across all Canadian provinces for these strains, as well as for its Highly Dutch mainstream portfolio which includes its Organic Afghan Black hash in both 30% THC and 40% THC formats. The Company expects to launch its Marrakech Gold blonde hash in July 2021, and an Aged Hash in the near-term future to expand this portfolio.

On February 23, 2021, the Company announced that its wholly owned European subsidiary, HemPoland, is launching CannabiGold Sport – a line of hemp-derived CBD pre- and post-workout supplements designed for professional and recreational athletes. CannabiGold Sport oils are available in five different formulations, each developed to support sport enthusiasts at different stages of their training. They contain different plant-derived ingredients and vitamins, combined with pure CBD in coconut MCT oil.

The ingredients used in the CannabiGold Sport line are obtained using HemPoland's proprietary supercritical carbon dioxide (CO₂) extraction technique developed specifically for hemp, the result of several years of research and development. The outcome is a CBD without the use of any synthetic cannabinoids, that the Company believes is of the highest quality.

The CannabiGold Sport line complements HemPoland's existing CannabiGold portfolio which comprises oil, capsules, and cosmetics. The new line will initially be distributed in Poland, Germany, and the UK, with plans to expand distribution to other European countries where CannabiGold products are already available. Distribution outside of Europe could be considered at a later stage.

United States of America (“US”) Market Entry Plans

With the continued regulatory progress in the US towards the decriminalization and legalization of cannabis in some form in various states, and the SAFE Banking Act passing through the US House of Representatives, the Company is accelerating its exploration of strategic options towards a potential US entry. Specific actions underway include discussions with investment advisors on potential acquisition and partnership opportunities, the potential expansion of the board to seven directors for the upcoming annual and special meeting of shareholders of the Company to add an additional nominee with US market experience, and consideration of applying for a listing on the Canadian Stock Exchange (“CSE”) which would allow for investment capability into the US.

Refer to the Company’s summary of regulatory framework for the US market in the “**Regulatory Landscape**” section below.

Other strategic initiatives

The Company continues to review other strategic initiatives to maximize shareholder value. This includes the potential sale or spin-off for an initial public offering of HemPoland, a wholly owned subsidiary of the Company, for which the Company has retained Canaccord Genuity Corp. as an advisor, and the potential for mergers and acquisitions in the Canadian cannabis licensed producers (“LP”) sector. The Company also continues to pursue international and partnership growth opportunities in Germany, Mexico and Australia. The Company is one of very few LP's with access to the Mexican market, with 4 SKUs already well into the review process by the COFEPRIS. In Australia, the Company continues to make progress with its in domestic partner for medical cannabis, LeafCann, and expects to move towards exporting product to Australia in the next few months.

Equity Issuances

In February 2021, the Company issued 14,341,958 Common Shares under the Company’s registered direct at-the-market prospectus supplement (“ATM”) dated on December 2, 2020 for gross proceeds of \$7,893. The ATM permits the Company to raise up to \$15,000 of Common Shares from time to time at a price equal to the then prevailing market price of the Common Shares at the time of each direction. Further availability for issuances under the ATM as at the date of this MD&A was \$7,107. The ATM is a supplement to the Company’s base shelf prospectus (“Base Shelf Prospectus”), qualifying the distribution of up to \$50,000 of securities of the Company to be raised through the issuance of various debt and equity securities of the Company over a period of up to 25 months from the date of the Base Shelf Prospectus which was filed on November 27, 2020. Further availability for additional prospectus supplements to be filed under the Base Shelf Prospectus is \$22,350 as at the date of this MD&A.

In February 2021, 24,197,600 warrants of the Company were exercised by certain warrant holders for gross proceeds of \$7,559, resulting in the issuance of 24,197,600 Common Shares.

COVID-19

The Company continues to monitor and adapt to changing market conditions including but not limited to the ongoing impact of the COVID-19 pandemic. See “Risk Factors”. The Company has implemented several operational and financial responses to address the COVID-19 pandemic. Specifically, the Company has:

- implemented precautionary measures at all Canadian locations to ensure the safety of the staff and product, including limiting visits to the site to essential personnel only, ensuring proper protocols around sanitation, mask usage and physical distancing and ensuring potentially exposed employees remain in self-quarantine for the appropriate period.

Cultivation is continuing and ongoing and additional licensed space available in the processing centre at the Hamilton Facility allows for better physical distancing among its cultivation and processing employees. The Company's Polish operations has implemented a similar response in line with local health guidelines in Poland.

- identified non-core assets that could be sold, leased, or otherwise monetized, particularly at its Quebec Facility which it has classified as separately in its Q1-2021 Interim Consolidated Financial Statements as assets held for sale for \$43,200.
- reduced its executive leadership group by seven members prior to December 31, 2020 and thus the Company incurred lower personnel costs associated with its leadership group in Q1-2021. The Company reinstated the remaining executive personnel that were affected by the Company's cash compensation reductions back to 100% pay effective January 1, 2021 which was previously reduced by 20% to 30% since April 1, 2020; and
- obtained \$987 in wage subsidies in 2020 from the Canadian federal government under the Canada Emergency Wage Subsidy ("CEWS"). With the Company's revenue growth year-over-year, it does not believe it will continue to be eligible for this program as it stands. However, the Company continues to monitor its eligibility for various government support programs in 2021.

OVERALL PERFORMANCE

The focus of the Company's activity is the ramp up of commercial operations and the production and sale of its organically grown cannabis products in order to achieve positive Canadian operating cash flows. In addition to its Canadian operations, the Company, through its subsidiaries and strategic investments, is pursuing an international growth strategy.

As described in the "Recent Developments" section above, the Company continues to launch its newly commercialized products. In Canada, the Company continues to improve its harvest quantities and qualities in line with its plan. In addition, the Company continues to seek new product listings from its largest customers which are provincial government cannabis boards. Listing its new products in each province will be a key catalyst to the future success of the Company. The Company reviewed available industry information stating that usage of cannabis products has increased during the pandemic. However, the Company believes that the COVID-19 pandemic has had and will continue to have adverse effects on distribution to final end user customers, causing uncertainty with respect to:

- retail sales restrictions are assessed provincially and regionally which can cause distribution impediments such as store closure, no in-store shopping, pick up shopping and online sales only; these are outside of the Company's control and affect the timing of orders where the retail stores order from the provincial boards; and
- the supply chain may be similarly affected as to whether its suppliers meet the local requirements to operate or not.

Refer to "Summary of Key Quarterly Highlights" for further insights as to how those macroeconomic factors affected the Company's performance in Q1-2021.

SELECTED OPERATIONAL INFORMATION

SUMMARY OF KEY QUARTERLY HIGHLIGHTS – Q1-2021 as compared to Q1-2020 and Q4-2020

	Q1-2021	Q4-2020	Q3-2020	Q2-2020	Q1-2020	Q4-2019	Q3-2019	Q2-2019
Revenue	\$ 8,982	10,918	5,710	4,825	3,059	3,250	2,612	2,896
Loss from operations	\$ (5,893)	(11,396)	(6,338)	(9,881)	(15,258)	(17,742)	(19,810)	(16,417)
Reversal of impairment / (impairment) of Canadian CGU	\$ 21,811	-	(67,837)	-	(52,765)	(123,432)	-	-
Impairment of European CGU	\$ -	(8,644)	-	-	-	-	-	-
Impairment of investment in associates	\$ -	-	-	-	(3,082)	(4,296)	-	-
Net income (loss)	\$ 12,463	(23,676)	(76,244)	(9,775)	(73,436)	(144,753)	(20,303)	(16,603)
Comprehensive income (loss)	\$ 11,159	(23,874)	(75,627)	(10,044)	(71,090)	(144,520)	(21,237)	(17,306)
Net income (loss) per share (basic & diluted)	\$ 0.02	(0.05)	(0.20)	(0.03)	(0.23)	(0.52)	(0.07)	(0.06)

Revenues

Revenue recognized in Q1-2021 amounted to \$8,982, an increase of 194% versus the prior year (Q1-2020 - \$3,059) with sales from cannabis products in Canada of \$6,668 and hemp derived sales by HemPoland of \$2,314. The Company's revenue in the prior year consisted primarily of HemPoland's product lines of \$2,395 as the Company had not yet developed or launched its current Highly Dutch flower and hash products which were launched later in 2020. Revenue decreased by 18% in comparison to Q4-2020 revenue of \$10,918 primarily in line with the Company's expectations for a decrease in sales in Canada in Q1-2021 due to the impact of store capacity and operating restrictions and stay-at-home orders related to COVID-19 protocols, combined with some provincial listing mandates being revised at the start of the year. The decrease in revenue for Q1-2021 for the Company is similar to what has been observed and reported by peer companies to date. The Company does however project growth to rebound later in 2021 once restrictions are lifted and stores can reopen. As the market continues to evolve, consumers have higher expectations from licensed producers, and the Company is also still competing with the illegal market which is not regulated, which therefore demonstrates the importance of going to market with high-quality, differentiated products.

Management continues to proactively manage costs to correlate with sales activity levels, as can be seen below.

Gross profit (loss)

	Three months ended				Three months ended		
	March 31, 2021	March 31, 2020	Variance to Q1-2020 (\$)	Variance to Q1-2020 (%)	December 31, 2020	Variance to Q4-2020 (\$)	Variance to Q4-2020 (%)
Net Revenue	7,703	2,931	4,772	163%	9,264	(1,561)	(17%)
Cost of sales	6,364	1,916	4,448	232%	8,279	(1,915)	(23%)
Gross profit before change in fair value of biological assets	1,339	1,015	324	32%	985	354	36%
Realized fair value adjustment on sale of inventory	(1,530)	(545)	(985)	181%	(2,324)	794	(34%)
Unrealized gain on changes in fair value of biological assets	3,321	1,236	2,085	169%	452	2,869	635%
Gross profit (loss)	3,130	1,706	1,424	83%	(887)	4,017	(453%)

The Company's gross profit before changes in fair value adjustments of biological assets was \$1,339 for Q1-2021 representing 17.4% direct gross margin (Q1-2020 - \$1,015, being 34.6% direct gross margin) primarily as a result of increased volumes of sales in Canada of \$6,004 for the quarter which carried lower margins due to significant fixed costs of operating the Company's facilities limiting the expected economies of scale at the current sales activity levels, and that the cost of sales figure in Q1-2021 includes \$633 of non-recurring property tax reassessments. The Company believes its direct gross margins in Canada will be approximately 30% to 40% once it is able to achieve revenue of at least \$5,000 per month.

The Company experienced a gross profit for Q1-2021 of \$3,130 (Q1-2020 - \$1,706) primarily driven by an increased unrealized gain on changes in fair value of biological assets partially offset by lower margin sales, and a higher realized fair value adjustment on the sale of inventory sold during the period. In comparison to Q4-2020, the gross profit increased by \$4,017, mainly as a result of an increased unrealized gain on changes in fair value of biological assets, as well as a lower realized fair value adjustment on the sale of inventory and an increase in direct gross margin of \$354.

Sales and marketing expenses

	Three months ended				Three months ended		
	March 31, 2021	March 31, 2020	Variance to Q1-2020 (\$)	Variance to Q1-2020 (%)	December 31, 2020	Variance to Q4-2020 (\$)	Variance to Q4-2020 (%)
Personnel costs	612	747	(135)	(18%)	786	(174)	(22%)
Third party marketing expenses	520	910	(390)	(43%)	621	(101)	(16%)
Travel and promotion expenses	33	79	(46)	(58%)	22	11	50%
Strategic partnership payments	184	645	(461)	(71%)	935	(751)	(80%)
Other marketing expenses	52	82	(30)	(37%)	86	(34)	(40%)
	1,401	2,463	(1,062)	(43%)	2,450	(1,049)	(43%)

Sales and marketing expenses of \$1,401 for the three-months ended March 31, 2021 decreased in comparison to expenses of \$2,463 for the same period in the prior year primarily due to additional work being performed in house with increased efficiencies rather than work performed by external consultants, and less spending on brand development. This is consistent with the Company's plan for cost cutting initiatives previously announced in 2020 that continued into 2021.

In comparison to Q4-2020, sales and marketing expenses decreased in Q1-2021 by \$1,049 primarily due to strategic partnership payments being paid on a new set of key performance indicators, and continued cost cutting initiatives.

Research and development expenses

	Three months ended				Three months ended		
	March 31, 2021	March 31, 2020	Variance to Q1-2020 (\$)	Variance to Q1-2020 (%)	December 31, 2020	Variance to Q4-2020 (\$)	Variance to Q4-2020 (%)
Personnel costs	243	378	(135)	(36%)	199	44	22%
Product development	36	86	(50)	(58%)	47	(11)	(23%)
Travel related expenses	16	22	(6)	(27%)	20	(4)	(20%)
Other research and development expenses	47	34	13	38%	-	47	n/a
Termination benefits	125	-	125	n/a	-	125	n/a
	467	520	(53)	(10%)	266	201	76%

Research and development expenses of \$467 for the three-months ended March 31, 2021 decreased in comparison to expenses of \$520 for the same period in the prior year. The Company incurred higher R&D costs in the prior year working on new product formulations and has now successfully commercialized organic cannabinoid dissolvables in Canada under the TGOD-Infusers line which began selling at the end of Q1-2020, and edibles in the form of its Blood Orange Gummies. Similar costs were not incurred in Q1-2021 due to the products already being available and reduced spending in line with the Company's cost cutting initiatives.

In comparison to Q4-2020, research and development expenses remained materially consistent, increasing by only \$201, which was primarily due to termination benefits incurred of \$125.

General and administrative expenses (“G&A”)

	Three months ended				Three months ended		
	March 31, 2021	March 31, 2020	Variance to Q1-2020 (\$)	Variance to Q1-2020 (%)	December 31, 2020	Variance to Q4-2020 (\$)	Variance to Q4-2020 (%)
Personnel costs	2,210	4,915	(2,705)	(55%)	2,604	(394)	(15%)
Office and other administrative expenses	1,039	2,372	(1,333)	(56%)	1,405	(366)	(26%)
Third party professional, consulting, legal fees	1,100	2,230	(1,130)	(51%)	1,632	(532)	(33%)
Computer and IT expenses	187	275	(88)	(32%)	241	(54)	(22%)
Termination benefits	19	-	19	n/a	(334)	353	(106%)
	4,555	9,792	(5,237)	(53%)	5,548	(993)	(18%)

⁽¹⁾ The Company recognized a \$404 credit of termination benefits in Q4-2020 due to it being able to settle the previously accrued amounts to former executive employees in shares rather than in cash. The corresponding expense was reclassified to share based compensation.

G&A expenses of \$4,555 for the three months ended March 31, 2021 decreased in comparison to expenses of \$9,792 for the same period in the prior year. The decrease of \$5,237 is mainly related to the reduction of personnel costs and third-party professional, consulting and legal costs.

In comparison to Q4-2020, G&A expenses decreased by \$993 which is mainly related to the reduction of personnel costs and third-party professional, consulting and legal costs, all in line with the Company’s cost cutting initiatives.

Share-based compensation expenses

The Company recognized a share-based compensation expense of \$613 for the three months ended March 31, 2021 compared to \$2,470 for the same period in the prior year. Share-based compensation was valued using the Black-Scholes valuation model and represents a non-cash expense. The decrease is primarily due to a reduction in the grant date fair value of new options granted, which is primarily attributable to the decline in the Company’s stock price from early 2020 and market volatility.

In comparison to Q4-2020, share-based compensation expense increased by \$318 primarily due to a reduction in forfeitures of certain employee options as there were less terminations that occurred in Q1-2021.

Loss from operations

Losses from operations were \$5,893 for the three months ended March 31, 2021 compared to \$15,258 for the same period in the prior year primarily driven by the increase in revenue and the implementation of cost cutting measures and resulting decreased operating expenses.

In comparison to a loss from operations of \$11,396 in Q4-2020, the Company’s loss from operations for Q1-2021 was lower due to reductions in operating expenses as noted above and higher fair value adjustment gains related to biological assets and inventory.

Reversal of impairment

Upon classifying the Company's Quebec Facility as assets held for sale on the Company's statement of financial position for \$43,200, the Company was required under IAS 36 – Impairment of long lived non-financial assets, to perform an impairment analysis on its Canadian Cash Generating Unit (“Canadian CGU”). The ending result was a non-cash reversal of impairment of \$21,811 for the three months ended March 31, 2021 (three months ended March 31, 2020 – impairment charge of \$52,762) primarily due to the excess capacity at the Quebec Facility being monetized which provides a higher return on the Company’s remaining assets in the Canadian CGU using a discounted cash flow analysis. The Canadian CGU’s value in use was estimated by discounting the probability weighted future cash flows expected to be generated from the continuing use of the Canadian CGU using level 3 inputs. The significant assumptions applied in the determination of the recoverable amount were materiality consistent with the impairment analysis performed as at December 31, 2020 such as the 16.5% discount rate, with the exception of the inclusion of the expected proceeds from the assets held for sale, partially offset by certain new operating costs to be incurred by the Canadian CGU over the period of the forecast. This non-cash impairment recovery does not directly impact the Company’s operating activities or liquidity.

In Comparison to Q4-2020, the Company recognized an impairment charge of \$8,644 in Q4-2020 to the Goodwill related to its investment in HemPoland forming its European cash generating unit (“European CGU”).

Net income (loss)

The Company’s net income for the three months ended March 31, 2021 was \$12,463 (three months ended March 31, 2020 – loss of \$73,436) which is comprised primarily of the reversal of impairment, and loss from operations discussed above.

Comprehensive income (loss)

The Company’s comprehensive income for the three months ended March 31, 2021 was \$11,159 (three months ended March 31, 2020 – loss of \$71,090) and is comprised of the net income discussed above and other comprehensive losses which is comprised of foreign exchange translation losses from foreign operations.

In comparison to Q4-2020, the Company’s comprehensive income in Q1-2021 increased by \$35,033 primarily due to the reversal of impairment and lower loss from operations.

FINANCIAL POSITION

The table below summarizes selected information regarding the Company’s financial position for the periods presented in accordance with IFRS and on a consistent basis with the interim consolidated financial statements and related notes:

	As at March 31, 2021	As at December 31, 2020	As at December 31, 2019	As at January 1, 2019*
Total assets	\$ <u>232,192</u>	\$ <u>211,575</u>	\$ <u>342,181</u>	\$ <u>447,236</u>
Total non-current liabilities	\$ <u>5,195</u>	\$ <u>5,394</u>	\$ <u>21,354</u>	\$ <u>3,591</u>
Total shareholders' equity	\$ <u>167,537</u>	\$ <u>139,804</u>	\$ <u>267,600</u>	\$ <u>413,655</u>

* The Company adopted IFRS 16 – Leases on January 1, 2019 and reflected transitional opening balance sheet adjustments as a result.

The following is a discussion of the significant changes to selected balances in the Company’s financial position as at March 31, 2021 as compared to December 31, 2020 in accordance with IFRS and on a consistent basis with the interim consolidated financial statements and related notes.

Assets

The Company’s consolidated cash and cash equivalents of \$16,519 as at March 31, 2021 (cash in Canada was approximately \$14,619) increased from \$11,212 as at December 31, 2020 primarily as a result of funds provided by financing activities. The Company’s trade receivables of \$5,217 as at March 31, 2021 (December 31, 2020 - \$10,023) represented collections of receivables from Q4-2020 coupled with decreased sales for the three months ended March 2021 compared to Q4-2020. As at March 31, 2021, the Company had \$19,843 in inventory as compared to \$17,135 as at for December 31, 2020 as a result additional cannabis inventory due to increased yields from cannabis plants in Q1-2021. The Company’s property plant and equipment decreased by \$28,734 to \$118,529 primarily as a result of \$43,200 reclassified to assets held for sale in current assets, partially offset by a recovery of \$21,811 non-cash impairment charges.

Liabilities

The Company’s accounts payable and accrued liabilities, including non-current accrued liabilities was \$16,069 as at March 31, 2021 reduced from \$24,453 as at December 31, 2020, with the decrease primarily relating to payments made against outstanding vendor payables. These payments were funded in part by additional funds received from the issuance of common shares as well as funds received from the exercise of warrants during the quarter.

The Company’s current portion of loans payable amounted to \$42,259 at March 31, 2021 as compared to \$40,755 as at December 31, 2020 primarily due to accretion as the loans move towards maturity on December 15, 2021 and December 31, 2021, and an

increase in drawn balance on the Company’s secured revolving credit facility entered into on April 22, 2020 (the “Revolver Loan”), partially offset by repayments on the Company’s senior secured first lien credit facility (the “Senior Secured Credit Facility”).

Equity

The Company’s Shareholders’ equity increased from \$139,804 as at December 31, 2020 to \$167,537 primarily due to an decrease in the accumulated deficit of \$12,518, an increase in share capital of \$16,918, and non-controlling interest of \$386 partially offset by a decrease in contributed surplus of \$790 and changes to reserve for foreign currency translations of \$1,299.

LIQUIDITY AND CAPITAL RESOURCES

During the three months ended March 31, 2021, the Company generated its revenue from domestic cannabis and international hemp operations and relied on the equity financings raised, together with draws on the Revolving Loan, to finance its operations and meet its capital requirements. The Company’s objectives when managing its liquidity and capital resources are to maintain a sufficient capital base to maintain investor and creditor confidence and to sustain the future development of the business.

As at March 31, 2021 the Company had a consolidated working capital of \$32,163 (December 31, 2020 - \$21,997 negative working capital) primarily due to the Company reclassifying certain assets held for sale as a current asset as at March 31, 2021 in accordance with IFRS 5 – Non-current assets held for sale and discontinued operations, and due to funds received from ATM equity financings and warrant exercises in the quarter. The total consolidated cash position was \$16,778, including \$259 of restricted cash (December 31, 2020 – \$11,834 of which \$622 was restricted cash). This cash will be used primarily towards covering working capital requirements and operating costs as the Company moves towards achieving positive operating cashflow, expected on a monthly basis later in 2021.

The Company has primarily financed its operations to date through the issuance of Common Shares, warrants, and draw-downs on certain of the Company’s debt facilities. The Company may need to further reschedule its debt or obtain capital through various means including the issuance of equity and/or debt to repay its obligations. The interim consolidated financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future if revenue plans, asset sales, debt refinancing and/or additional debt or equity financing or any combination thereof is received. There can be no assurance that additional funding will be available to the Company, or, if available, that this funding will be on acceptable terms. If adequate funds are not available, the Company may be required to delay or reduce the scope of any or all of its projects. These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company’s ability to continue as a going concern.

	For the three months ended		
	March 31, 2021	March 31, 2020	Variance to Q1-2020 (\$)
Net cash used in operating activities	\$ (5,537)	\$ (13,097)	\$ 7,560
Net cash used in investing activities	(1,941)	(16,925)	14,984
Net cash provided by financing activities	13,651	6,472	7,179
Net effects of foreign exchange	(866)	828	(1,694)
(Decrease) increase in cash and cash equivalents	\$ 5,307	\$ (22,722)	\$ 28,029

Operating Activities

For the three months ended March 31, 2021 net cash used in operating activities was \$7,560 lower than the three months ended March 31, 2020. The decrease was achieved primarily due to the effect of cost reductions initiatives for the three months ended March 31, 2021.

Investing Activities

For the three months ended March 31, 2021 net cash used in investing activities was \$14,984 lower than the three months ended March 31, 2020. The decrease was primarily the result of a reduction in capital expenditures as well as due to proceeds of \$1,242 received in connection with the sale of Califormulations and the monetization of certain capital equipment in the period.

Financing Activities

For the three months ended March 31, 2021, net cash provided by financing activities was \$7,179 higher than the year ended March 31, 2020. The increase was primarily the result of an additional \$7,655 proceeds from the issuance of shares in the period as well as additional \$7,135 proceeds from exercise of warrants during the period compared to the three months ended March 31, 2020.

The increase was primarily offset by a decrease of \$6,658 in cash proceeds related to the issuance of debt in comparison to the three months ended March 31, 2020.

Contractual obligations

The Company had the following estimated gross contractual obligations as at March 31, 2021, which were expected to be payable in the following respective periods:

	Contractual cash flows - 12 months ending							
	Carrying amount	Total	March 2022	March 2023	March 2024	March 2025	March 2026	Thereafter
	\$	\$	\$	\$	\$	\$	\$	\$
Accounts payable and accrued liabilities	16,069	16,069	16,069	-	-	-	-	-
Loans	42,259	49,295	49,295	-	-	-	-	-
Lease liabilities	5,390	8,639	1,038	981	846	815	720	4,239
Total contractual obligations	63,718	74,003	66,402	981	846	815	720	4,239

⁽¹⁾ Contractual cash flows include expected interest payable until the maturity date.

The Company's accounts payable and accrued liabilities include consolidated trade payables and accrued liabilities for work incurred, including for the construction of the facilities and the payables related to its licencing revenue stream.

The contractual cash flows in the table above include the relevant interest and principal payments related to the total of \$31,513 drawn on the Senior Secured Credit Facility and the \$14,401 now drawn on the Revolver Loan as at March 31, 2021 payable until maturity dates. The Company expects further draws on the \$17,000 available under the Revolver Loan secured by trade receivables, over the balance of 2021 for which it will have to incur interest charges based on actual uses. The Company may repay the principal on the Senior Secured Credit Facility at any time with a 2% penalty on the outstanding principal. As described in the 'Recent Developments' section above, the Company is proactively evaluating opportunities such as monetizing its Quebec Facility in whole or in part, in combination with utilizing the remaining room under its Base Shelf Prospectus. Where and if additional financing becomes available, such as from asset sales or from warrant exercises, the Company will consider making prepayments against its facilities to implement savings of interest charges of between 12% and 13%.

The Company's leased liabilities are valued in accordance with IFRS where the Company has recognized an increase to both assets and liabilities on the consolidated statements of financial position, as well as a decrease to operating expenses (for the removal of rent expense for leases), an increase to depreciation and amortization (due to depreciation of the right-of-use assets), and an increase to finance costs (due to accretion of the lease liability).

The contingent consideration payable relates to contingent consideration of up to 656,784 shares potentially payable to the former owners of HemPoland based on that entity achieving certain earnings targets by the end of the 2021 financial year which may be settled in cash pursuant to the terms of the agreement at the Company's option. The consideration is revalued to fair value at the end of each reporting period in accordance with IFRS based on a valuation technique with a probability assessment of asymmetric payment structures.

Other Contractual Commitments

The lease for the office space of the Company's headquarters required the issuance of a letter of credit in the amount \$350, which may be drawn upon by the landlord in the event of a material breach of the agreement. As at March 31, 2021, there have been no breaches and no amounts have been drawn upon this letter of credit.

Pursuant to some of the agreements related to the Company's Hamilton Facility, as at March 31, 2021, the Company has letters of credit in the amount of \$585 which may be drawn upon in the event of material breaches of the respective agreements. These letters of credit bear conventional rates of interest partially offset by the interest earned on guaranteed investment certificates ("GIC") securing the letters as collateral. The Company has pledged corresponding GICs as collateral, which has been recorded in other assets. As at March 31, 2021, there have been no breaches and no amounts have been drawn on the letters of credit.

The Company has also entered into certain agreements for equipment and services that allow for deferred payment terms and/or the inclusion of permitted subordinated liens on personal property, per the Senior Secured Credit Facility agreement, associated with the equipment located at both the Hamilton Facility and the Quebec Facility should there be any material breaches of the agreements. As at March 31, 2021, there have been no breaches of the respective agreements.

Claims and Litigation

The Company may become subject to litigation from time to time in the ordinary course of business, some of which may adversely affect its business. For instance, the Company is currently, at the date of this MD&A, subject to one employment-related claim for approximately \$3,000, a breach of contract claim by former warrant holders for approximately \$1,250, a civil claim in the United States District Court for the Middle District of Georgia, and a claim from a customer in Europe for approximately \$2,100. The employment claim relates to a former contract CFO of the Company. The former contract CFO issued a claim in the Ontario Superior Court of Justice for damages of \$3,000 on September 25, 2018 and the Company filed a defence in October 2018 where management responded that it believes the claim is without merit. There have been no appearances or proceedings scheduled since the Company's defence was filed. In the breach of contract claim, a group of plaintiffs have brought a claim in British Columbia alleging breach of contract in regard to share purchase warrants they were prevented from exercising due to a restrictive trading period. This matter has been set down for trial commencing July 19, 2021. On August 3, 2020, the Company was named as a defendant in a civil litigation matter commenced in the United States District Court for the Middle District of Georgia relating to its minority interest in a US-based beverage incubation business, seeking, among other things, unquantified compensatory damages and injunctive relief. The Company believes this claim against it is without merit and intends to vigorously defend the matter. Finally, a customer in Europe (a distributor) alleges that HemPoland breached a verbal contract with it by ceasing to cooperate with the distributor and has alleged damages of approximately \$2,100. No proceedings have been initiated in respect of the matter.

Should any of these claims or any other litigation in which the Company becomes involved be determined against the Company, such a decision could adversely affect the Company's ability to continue operating, the value or market price for the Common Shares and could require the use of significant resources. Even if the Company is involved in litigation and is ultimately successful, litigation can require the redirection of significant resources. Litigation may also create a negative perception of the Company's brand.

Use of Proceeds from Previous Financings

The Company included a detailed disclosure of the Company's intended use and actual use of proceeds for financings in 2020 in the Company's December 31, 2020 MD&A. The following table compares the Company's previous disclosure on its intended use of proceeds from the most recent offering with the subsequent actual use of those proceeds in Q1-2021, together with an explanation of any variances and the impact of those variances, if any, on the Company's ability to achieve its current business objectives:

Financing	Disclosed intended use of net proceeds	Actual use of proceeds and discussion of variances
December 2020 Units	Repayment of construction indebtedness and other payables - \$9,250, net of transaction costs	<p>The Company only partially used the net proceeds of the December Offering and drew less on its Revolver Loan than anticipated for the remainder of December 2020 to save on interest costs given it had sufficient cash on hand. The Company believed that this provides additional flexibility for monetization options in future periods which is further described in the Liquidity and Resources section.</p> <p>Primarily in December 2020, the Company purchased the remaining of the outstanding shares of QuebecCo for \$750 to fully own and control the property on which the Quebec Facility is situated given it had cash on hand from the financing. The Company believes that this provides additional flexibility for monetization options in future periods which is further described in the Liquidity and Resources section.</p> <p>In Q1-2021, the Company used the remaining funds as intended by funding its operations, payable and funding for negative cash flows until it was expected to achieve positive Canadian operating cash flows expected which was beyond the March 31, 2021 timeframe.</p> <p>The Company's additional cash inflows from its ATM and proceeds from the exercise of warrants in Q1-2021 were</p>

		sufficient to allow the Company to achieve its stated objectives to date in 2021.
ATM proceeds	General corporate purposes, working capital, including the repayment of indebtedness	The Company used the funds raised during the ATM of \$7,655 as intended.

OFF-BALANCE SHEET ARRANGEMENTS

As at the date of this MD&A, the Company had no material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the financial performance or financial condition of the Company.

CRITICAL ACCOUNTING ESTIMATES, JUDGEMENTS AND CHANGES IN ACCOUNTING POLICIES

Except as disclosed in Note 3 to our interim consolidated financial statements, there were no significant changes in our accounting policies and critical accounting estimates for the three months ended March 31, 2021. We describe our significant accounting policies and critical accounting estimates in Note 3 to the audited consolidated financial statements and MD&A for the year ended December 31, 2020. The preparation of the interim consolidated financial statements requires the use of estimates and judgements that affect the application of the Company's accounting policies and reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods effected.

[i] New standards, interpretations and amendments adopted by the Company

Non-current assets (or disposal groups) held for sale

Non-current assets (or disposal groups) are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Assets held for sale are measured at each reporting period at the lower of their carrying amount and fair value less costs to sell ("FVLCS"), except for inventories, biological assets, deferred tax assets, assets arising from employee benefits, financial assets and investment property that are carried at fair value and contractual rights under insurance contracts, which are measured in accordance with the Company's other accounting policies, as applicable.

An impairment loss is recognized for any initial or subsequent write-down of the assets held for sale (or disposal group) to FVLCS. A gain is recognized for any subsequent increases in FVLCS of assets held for sale (or disposal group), but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the non-current assets (or disposal group) is recognized at the date of derecognition.

Non-current assets (including those part of a disposal group) are not depreciated or amortized while they are classified as held for sale. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognized.

Non-current assets classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet.

FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

[a] Fair values

The Company's financial instruments were comprised of the following as at March 31, 2021: cash and cash equivalents; restricted cash; refundable sales tax receivable; trade receivables; due from related parties; other investments, other current assets; accounts payable and accrued liabilities; short-term loans; contingent consideration and lease liabilities.

The fair values of the financial assets and financial liabilities are determined at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The assumption for the instrument's recorded at amortized cost is that the instrument's fair value approximates their carrying amount is largely due to the short-term maturities of these instruments.

[b] Fair value hierarchy

Financial instruments recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value. During the three months ended March 31, 2021, there were no transfers of amounts between levels (year ended December 31, 2020 – no changes).

[c] Management of key risks arising from financial instruments

Credit Risk

As at March 31, 2021, the Company's trade receivables are primarily concentrated in Canada with the exception of \$555 in Europe. The Company had three customers whose balances was individually greater than 10% of total trade receivable as at March 31, 2021 (December 31, 2020 – two customers).

RELATED PARTY TRANSACTIONS

Identification of related parties

Related parties as at March 31, 2021 have been identified as follows:

Related party	Business relationship	Measurement basis
Jeffrey Scott	Director	Exchange amount
Nicholas Kirton	Director	Exchange amount
Marc Bertrand	Director	Exchange amount
Jacques Dessureault	Director	Exchange amount
Caroline MacCallum	Director	Exchange amount
Sean Bovingdon	Management	Exchange amount
Matthew Schmidt	Management	Exchange amount
Michel Gagne	Management	Exchange amount

Key transactions with related parties

There have been no material transactions with related parties and no unusual transactions outside of the normal course of business during the three months ended March 31, 2021. None of the balances outstanding to related parties as at March 31, 2021 are secured (March 31, 2020 – none). No expense has been recognized in the current period or prior period for bad or doubtful debts in respect of amounts owed by related parties. No new guarantees have been given or received by related parties during the three months ended March 31, 2021. As at March 31, 2021, the Company had no receivable or payable balances with key management personnel and \$172 of director fees payable (March 31, 2020 - \$127).

REGULATORY LANDSCAPE

The results of operations and financial condition of the Company are subject to a number of regulations and are affected by a number of factors outside the control of management.

Canadian Regulatory Landscape

The production, distribution and sale of Cannabis in Canada is strictly regulated. On October 17, 2018, the federal Cannabis Act and accompanying Regulations, including the Cannabis Regulations (“Cannabis Regulations”), the new Industrial Hemp Regulations (“IHR”, and together with the Cannabis Regulations, collectively, the “Regulations”), came into force, legalizing the production, distribution and sale of cannabis for adult recreational purposes, as well as incorporating the pre-existing medical cannabis regulatory scheme under one complete framework. Amendments legalizing the sale of edible cannabis, cannabis extracts, and cannabis topicals in the Canadian market came into force on October 17, 2019. A federally licensed entity with authorization to produce and sell a class of cannabis (except plants and seeds) must provide 60-days notice to Health Canada of its intent to sell any new cannabis retail product prior to making such product available for sale to provincially authorized purchasers or medical users.

Pursuant to the federal regulatory framework in Canada, each province and territory may adopt its own laws governing the distribution, sale and consumption of cannabis and cannabis accessories within the province or territory provided that the provincial or territorial legislation contains certain measures that mirror the public health policy goals of the federal regime. All Canadian provinces and territories have implemented mechanisms for the distribution and sale of cannabis for recreational purposes within those jurisdictions, and retail models vary between jurisdictions.

The Cannabis Act maintains separate access to cannabis for medical purposes, including providing that import and export licences and permits will only be issued in respect of cannabis for medical or scientific purposes or in respect of industrial hemp. Patients who have the authorization of their healthcare provider may register with Health Canada to have access to cannabis, either purchased directly from a federally licensed entity authorized to sell for medical purposes, or by registering to produce a limited amount of cannabis for their own medical purposes or designating someone to produce cannabis for them.

Provincial Regulatory Framework for Recreational Cannabis

While the Cannabis Act provides for regulation of the commercial production of cannabis and related matters by the federal government, the provinces and territories of Canada have authority to adopt their own laws and regulations governing the distribution, sale and consumption of cannabis and cannabis accessory products within the province or territory, permitting for example, provincial and territorial governments to set lower possession limit for individuals and higher age requirements. Currently each of the Canadian provincial and territorial jurisdictions has established a minimum age of 19, except for Alberta, where the minimum age is 18, and Québec, where the minimum age is 21.

All Canadian provinces and territories have implemented regulatory regimes for the distribution and sale of cannabis for recreational purposes within those jurisdictions. In most provinces, provincial/territorial crown corporations act as intermediaries between entities licensed federally under the Cannabis Act and consumers, such bodies acting in some jurisdictions as exclusive cannabis wholesalers and distributors, and in some instances as exclusive retailers.

Some provinces also authorize municipal governments to impose additional requirements and regulations on the sale of recreational cannabis, such as by restricting the number of recreational cannabis retail outlets that are permitted in a certain geographical area. Municipal zoning authority also generally permits a municipality to restrict the geographical locations wherein such retail outlets may be opened.

Regulatory Landscape Outside Canada

The Company only conducts business in jurisdictions outside of Canada where such operations are legally permissible in accordance with all of the laws of the foreign jurisdiction, the laws of Canada and the rules of the TSX. The legal and regulatory requirements in the foreign countries in which the Company operates with respect to the cultivation and sale of cannabis, as well as local business culture and practices, are different from those in Canada. Prior to commencing operations in a new country, in partnership with local legal counsel, consultants and partners, the Company conducts legal and commercial due diligence in order to ensure that the Company and its officers and directors gain a sufficient understanding of the legal, political and commercial framework and specific risks associated with operating in such jurisdiction. Where possible, the Company seeks to work with

respected and experienced local partners who can help the Company to understand and navigate the local business and operating environment, language and cultural differences. In consultation with advisors, the Company takes steps deemed appropriate in light of the level of activity and investment it expects to have in each country to ensure the management of risks and the implementation of necessary internal controls.

Poland

In Poland, the use of hemp is generally restricted and may be accepted only if certain statutory requirements are met. Polish laws provide specific regulations, depending on the use of the hemp. Pursuant to the Misuse of Drugs Act, hemp may be grown solely and exclusively for the needs of the textile, chemical, pulp and paper, food, cosmetic, pharmaceutical and construction industries, as well as for seed production. Buying hemp from a farmer requires a permit from the governor of the province holding territorial jurisdiction over the plantation. Where hemp extracts are used for producing foodstuffs, the production facility must meet the sanitary requirements stipulated under the Act on the Safety of Food and Nutrition. The cultivation of cannabis which does not fall within the definition of hemp under the Misuse of Drugs Act, i.e. “plant species *Cannabis Sativa L.*, in which the total content of delta-9-tetrahydrocannabinol and tetrahydrocannabinolic acid (delta-9-THC-2-carboxylic acid) in the floral or fructifying tops of the plants, from which resins has not been removed, does not exceed 0.20% of the dry-extract content” is prohibited in Poland.

Mexico

On June 19, 2017, Mexico enacted certain amendments to the General Health Law of Mexico, allowing the use of cannabis and its derivatives for medicinal purposes that could be commercialized and prescribed by any licensed physician and sold in pharmacies, as long as the products contain less than 1% THC, as well as for the sale of other products with broad industrial uses as long as a cumulative dose of 1% THC is not exceeded. On August 14, 2019, Mexico’s Supreme Court of Justice (the “Supreme Court”) resolved an amparo trial setting forth an obligation for the Ministry of Health to regulate the medical and therapeutic use of cannabis and its derivatives, to guarantee the human right to health to the public at large. A Bill was presented in Congress by the United Commissions of Justice, Health, and Legislative Studies of the Senate, to enact the Federal Law for the Regulation of Cannabis and the amendments to certain provisions set forth in the General Health Law and the Criminal Code (the “Bill”). On January 12, 2021, the Regulations of the General Health Law on sanitary control for the production, research and medicinal use of cannabis and its pharmacological derivatives was published in the Federal Official Gazette (the “Regulations”). The Regulations provides for the primary production for the supply and production of seed, research for health and pharmacology, manufacture of pharmacological derivatives and medicines, and the medicinal use of cannabis. However, it disregards whether to allow foreign investment or limit the percentage of its investment, the exclusivity of licenses and authorizations, nor does it limit the number of licenses that can be obtained per company or establishment, for one or all the regulated activities. The Regulations entered into force on January 13, 2021. Finally, on March 10, 2021, the Chamber of Deputies approved the general terms of the Bill, which was returned to the Senate to discuss certain amendments proposed by the Chamber of Deputies. The Bill regulates the following uses of cannabis and its derivatives: personal, commercialization for recreational purposes, scientific and/or research, and hemp production for industrial uses. The National Commission against Addictions (the “Commission”) and the Agriculture and Rural Development Ministry (the “SADER”) will be the governmental entities responsible for granting the licenses and permits required to carry out the activities regulated thereby. The Bill distinguishes between the following types of cannabis: a) psychoactive cannabis, containing THC (tetrahydrocannabinol) on a concentration that amounts to or more than 1% THC, and b) hemp or no-psychoactive cannabis, which does not produce a psychoactive effect and it contains a concentration that amounts to or less than 1% THC. The Bill does not limit the percentage of foreign investment for Mexican corporations eligible to request any license. In addition, it does not prohibit the use of “neutral investment”, as allowed in the Foreign Investments Law. A further analysis on this issue will be needed as the proposed legal framework for cannabis and future regulations evolves. As of this date the Bill has not been enacted.

United States

“Marijuana” is a Schedule I controlled substance under the United States Controlled Substances Act, as amended (the “CSA”). On December 20, 2018, the United States Agriculture Improvement Act of 2018 (as amended and commonly known as the “2018 Farm Bill”) redefined “marihuana” to exclude hemp (defined as *Cannabis sativa L.* with a delta-9 tetrahydrocannabinol (“THC”) concentration of not more than 0.3 percent on a dry weight basis) and its byproducts, resulting in the removal of the classification of hemp as a Schedule I controlled substance under the CSA. The declassification of industrial hemp opened the path for broad commercial cultivation of the crop and, among other things, the use of its byproducts in consumer goods, including cannabidiol derived from hemp (CBD). The 2018 Farm Bill does not affect any other cannabis product, and therefore cannabis and cannabis derivatives that do not meet the definition of hemp, and activities involving them, remain illegal under United States federal law.

The 2018 Farm Bill empowered the United States Department of Agriculture (the “USDA”) to implement a program to certify state and Indian tribe permitting for the commercial cultivation of hemp. On October 29, 2019, the USDA released an

interim final rule for regulations governing hemp production in the United States. After public comment, the USDA announced final rules on January 19, 2021, which became effective March 22, 2021. The Farm Bill also authorized territories, individual states and Indian Tribes to regulate hemp in their jurisdictions by developing and seeking USDA approval of a regulatory plan. As of April 20, 2021, USDA had approved 75 state, territorial, and tribal hemp plans.

Notwithstanding the 2018 Farm Bill, the United States Food and Drug Administration (the “FDA”) has the authority to regulate the production and sale of hemp pursuant to the Federal Food, Drug, and Cosmetic Act of 1938 (as amended, the “FCDA”), and section 351 of the Public Health Service Act (addressing the regulation of biological products). Shortly after the 2018 Farm Bill became law, the FDA issued a statement that any cannabis product, whether derived from hemp or otherwise, marketed with a disease claim (e.g., a claim of therapeutic benefit or disease prevention) must be approved by the FDA for its intended use through one of the drug approval pathways prior to it being introduced into United States interstate commerce.

Following the passage of the 2018 Farm Bill, the FDA also stated that introducing or delivering for introduction into United States interstate commerce food or beverages containing added CBD (or THC), regardless of source, is currently illegal under the FDCA. In December 2018, FDA completed its evaluation of three generally recognized as safe (GRAS) notices for three hemp seed-derived food ingredients: hulled hemp seed, hemp seed protein powder, and hemp seed oil and determined that these products can be legally marketed in human foods for the uses described in those notices, provided that they comply with all other requirements. In November 2019, FDA determined that based on the lack of scientific information supporting the safety of CBD in food, the agency could not conclude that CBD is GRAS for its use in human or animal food. Additionally, FDA has concluded that THC and CBD products cannot lawfully be marketed as dietary supplements.

Although enforcement under the FDCA may be civil or criminal in nature, the FDA has thus far limited its recent enforcement against companies manufacturing and/or marketing CBD products to warning letters alleging various violations of the FDCA, including, but not limited to, that the products bear claims that render the products unapproved and misbranded new drugs, that CBD is excluded from the FDCA’s definition of “dietary supplement,” and that the FDCA prohibits the addition of CBD to food. The FDA also tested some of the products, and found that many did not contain the levels of CBD they claimed to contain, which could be the basis for a separate violation of the FDCA. In addition, some states have taken actions to restrict or prohibit the sale of CBD products under state law. The FDA has signaled that it will likely issue further guidance and/or issue regulations concerning CBD products, although the contents and timing of such guidance and regulations remain unknown.

On August 20, 2020, the United States Drug Enforcement Agency issued interim final rules codifying the amendments to the CSA resulting from the 2018 Farm Bill. Among other things, the DEA rules state that any hemp derivative, extract, or product that exceeds the 0.3 percent THC concentration remains a Schedule I controlled substance, even if the plant from which it was derived contained 0.3 percent or less THC on a dry weight basis (i.e., hemp). The result of this rule making is that the DEA may consider any hemp extract that temporarily exceeds 0.3 percent THC concentration during the extraction process to be a Schedule I controlled substance, even if the THC concentration is subsequently reduced to 0.3 percent or less. These rules are currently effective, but are subject to adoption of final rulemaking by the DEA.

Germany

In March 2017, the German legislator introduced “The Cannabis as Medicine Act” (“Gesetz zur Änderung betäubungsmittelrechtlicher und anderer Vorschriften“) which regulates the requirements for the marketability of cannabis pharmaceuticals and their inclusion in health insurance plans. Under this Act, statutory insured patients suffering from a severe disease (i.e. life-threatening or seriously affecting quality of life) are entitled to treatment with medicinal cannabis (flowers or extracts in standardized quality) if (i) generally recognized treatment in accordance with medical standards is either not available, or cannot be applied in individual cases according to the justified assessment of the treating physician, and (ii) if there is a not entirely distant prospect of a noticeable positive effect on the course of the disease or on serious symptoms.

Importers of cannabis pharmaceuticals which have not been produced in an EU/EFTA Member State and which shall be distributed in Germany on a commercial or professional basis must apply for an import authorization to the competent health authority in the federal state (Bundesland) in which the importer is based pursuant to section 72 Medicinal Products Act (Arzneimittelgesetz – “AMG”). Generally, the import authorization can be issued for cannabis from cultivations controlled by the country of origin pursuant to the requirements of the 1961 UN Single Convention on Narcotic Drugs. Additionally, importers must apply for a manufacturing authorization pursuant to section 13 AMG if they carry out at least one manufacturing step within the meaning of section 4 (14) AMG (e.g. preparing, formulating, treating or processing, filling, decanting, packaging, labelling) after import. Furthermore, the distribution of drug products treated with radiation (e.g. E-Beam) requires a permit under the German Regulation on Drug Products treated with Radiation (Verordnung über radioaktive oder mit ionisierenden Strahlen behandelte Arzneimittel – “AMRadV”).

The marketing of medicinal cannabis products that qualify as finished medicinal products requires a marketing authorization issued by the competent Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte – “BfArM”).

Pursuant to sec. 72a AMG, importers of medicinal cannabis must ensure that their products have been produced in compliance with applicable quality standards and must obtain a written confirmation from a competent authority to prove compliance. In particular, cannabis medicinal products must be manufactured in compliance with the manufacturing standards of the Pharmaceuticals and Active Agent Manufacturing Ordinance (Arzneimittel- und Wirkstoffherstellungsverordnung – “AMWHV”) which implements the EU Good Manufacturing Practice (“EU GMP”). In addition to standards for the growing and cultivation of the cannabis plant itself, such as the Good Agricultural and Collection Practice (GACP), which is annexed to the EU-GMP, specific pharmaceutical quality standards must be met before placing the product on the market. Such standards are established by pharmaceutical monographs (e.g. “Cannabis Flowers”, “Cannabis Extract”), which are published by the BfArM in the German Pharmacopoeia (Deutsches Arzneibuch – “DAB”).

Finally, medicinal cannabis products with a THC concentration of at least 0.2 percent qualify as narcotics under German law and are therefore subject to the authorization requirements under the German Narcotic Drugs Act (Betäubungsmittelgesetz – “BtMG”). Under this Act, the seller, buyer and other processors (e.g. importers, distributors, etc.) of medicinal cannabis products must obtain an authorization by the BfArM. Such an authorization has been issued per se for qualified doctors and pharmacists who sell or buy narcotics for the treatment of a patient or in the course of the operation of a pharmacy. Although CBD as such is not subject to the BtMG unless the possible THC traces exceed 0.2 percent, it is currently unclear whether products containing CBD will be classified and marketed as industrial hemp products or food rather than narcotic drugs following a judgment from the Court of Justice of the European Union on November 19, 2020 and the European Commission’s ongoing review of applications for approval of products containing CBD as novel foods. In its ruling of March 24, 2021, the German Federal Court of Justice (Bundesgerichtshof - “BGH”) ruled that the sale of hemp flowers and leaves to end-consumers may qualify as a narcotic but is not necessarily prohibited under the BtMG, provided that these products serve exclusively commercial or scientific purposes without intent to cause intoxication

RISK FACTORS AND UNCERTAINTIES

Many factors could cause the Company’s results of operations, performance and financial condition to differ materially from those expressed or implied by the forward-looking statements and forward-looking information contained in this management’s analysis and discussion, including the following factors, which are discussed in greater detail under the heading “Risk Factors” in the Company’s current Annual Information Form as updated by subsequent reports, filed with securities regulators and available on www.sedar.com, which risk factors are incorporated by reference into this document and should be reviewed in detail by all readers:

- the ongoing impact of COVID-19;
- the Company’s ability to continue as a going concern;
- the Company’s ability to raise required additional capital through the sale of equity or debt instruments or the factoring of receivables or otherwise;
- the Company has a limited operating history;
- the Company may be unable to achieve revenue growth and development;
- there are factors which may prevent the Company from the realization of growth targets;
- the Company’s actual financial position and results of operations may differ materially from the expectations of the Company’s management;
- the Company may incur significant ongoing costs and obligations related to its investment in infrastructure, growth, research and development, regulatory compliance and operations;
- there is no assurance that the Company will turn a profit or generate immediate revenues;
- the Company’s management has broad discretion concerning the use of net proceeds of the ATM program;
- the Company is subject to risks typically associated with secured debt financing;
- the adult-use cannabis market in Canada is a relatively new industry;
- the adult-use cannabis market in Canada may experience supply and demand fluctuations that could result in revenue and price decreases;
- the size of the Company’s target market is difficult to quantify, and investors will be reliant on their own estimates on the accuracy of market data;
- the Company is subject to changes in laws, regulations and guidelines which could adversely affect the Company’s future business, financial condition and results of operations;
- the Company’s CBD business in Europe is subject to evolving approaches to the regulation of CBD by the European Union, its member states, and the United Kingdom;

- the Company's business is dependent on key supply chains which could be adversely disrupted by a number of factors including, among others, major health issues or pandemics;
- the Company is reliant on regulatory approvals and cultivation licences for its ability to grow, process, package, store and sell cannabis and other products derived therefrom, and these regulatory approvals are subject to ongoing compliance requirements, reporting obligations and fixed terms requiring renewal;
- any failure on the Company's part to comply with applicable regulations could prevent it from being able to carry on its business and there may be additional costs associated with any such failure;
- under Canadian regulations, a Licensed Producer of cannabis is restricted regarding the type and form of marketing it can undertake which could materially impact sales performance;
- the Company intends to target a premium segment of the adult-use cannabis market, which may not materialize to levels expected, or in which it may not be able to develop or maintain a brand that attracts or retains customers;
- the Company's industry is experiencing rapid growth and consolidation that may cause the Company to lose key relationships and intensify competition;
- the Company may be unsuccessful in competing in the overall legal adult-use cannabis market in Canada and any other countries it intends to operate in;
- the Company, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception;
- the Company's products may not have, or may not be perceived to have, the effects intended by the end user;
- the Company may not be able to develop its products, which could prevent it from ever becoming profitable;
- if the Company is unable to develop and market new products, such as beverages, it may not be able to keep pace with market developments;
- there has been limited study on the health effects of cannabis products, including CBD, and future clinical research studies may lead to conclusions that dispute or conflict with the Company's understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of such products;
- consumer preferences may change and the Company may be unsuccessful in retaining customer;
- trade of cannabis for non-medicinal purposes within Canada may be restricted by the Canadian Free Trade Agreement;
- the Company is exposed to risks relating to the laws of various countries as a result of its existing and planned international operations;
- the Company must rely on international advisors and consultants in the foreign countries in which it operates and intends to operate;
- the Company is required to comply concurrently with federal, state or provincial, and local laws in each jurisdiction where it operates or to which it exports its products;
- the hemp and CBD industries and markets are new and heavily regulated with rules subject to rapidly changing laws and uncertainty, compliance with which may come with significant cost;
- the hemp and CBD products industries and markets in Canada, the EU and Mexico are also subject to many of the same risks as the adult-use cannabis industry and market;
- if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the cannabis market;
- the Company has entered into and in the future may seek to enter into strategic alliances including contractual relationships, joint ventures, selective acquisitions, licensing arrangements or other relationships, or expand the scope of currently existing relationships, with third parties that the Company believes will have a beneficial impact, and there are risks that such strategic alliances or expansions of the Company's currently existing relationships may not enhance its business in the desired manner;
- the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations;
- the cultivation of cannabis includes risks inherent in an agricultural business including the risk of crop loss, sudden changes in environmental conditions, equipment failure, product recalls and others;
- the Company is reliant on key inputs, such as water and utilities, and any interruption of these services could have a material adverse effect on the Company's finances and operation results. The Company is also dependent on access to skilled labour, equipment and parts;
- the Company is vulnerable to rising energy costs;
- the Company's quality control systems may not operate effectively;
- the Company's cannabis products may be subject to recalls for a variety of reasons, which could require it to expend significant management and capital resources;
- the Company faces an inherent risk of exposure to product liability;
- the Company's operations are subject to safety, health and environmental laws and regulations applicable to its operations and industry in the various jurisdictions in which it operates, and it may be held liable for any breaches of those laws and regulations;
- the Company could be liable for fraudulent or illegal activity by its employees, contractors and consultants resulting in significant financial losses or claims against the Company;

- the Company may become subject to litigation in the ordinary course of business;
- the Company will be reliant on information technology systems and may be subject to damaging cyber-attacks;
- the Company may be exposed to liability or the threat of liability in relation to the use of customer information and other personal and confidential information;
- the Company may be subject to risks related to the protection and enforcement of its intellectual property rights, or intellectual property it licenses from others, and may become subject to allegations that it or its licensors are in violation of intellectual property rights of third parties;
- the Company may be subject to breaches of security at its facilities;
- the Company may incur additional indebtedness;
- management may not be able to successfully implement adequate internal controls over financial reporting;
- if the Company has a material weakness in its internal controls over financial reporting, investors could lose confidence in the reliability of the Company's financial statements, which could result in a decrease in the value of its securities;
- the Company has negative operating cash flow;
- the Company may be subject to credit risk;
- tax and accounting requirements may change in ways that are unforeseen to the Company and it may face difficulty or be unable to implement or comply with any such changes;
- fluctuations in foreign currency exchange rates could harm the Company's results of operations;
- U.S. border officials could deny entry into the U.S. to employees of or investors with cannabis operations in the United States and Canada;
- the Company may not be able to renew or secure adequate insurance to protect its assets, operations and employees;
- the price of the Common Shares in public markets may experience significant fluctuations;
- if securities or industry analysts do not continue to publish research, or publish inaccurate or unfavourable research, about the Company's business, the Common Share price and trading volume could decline;
- the Company continues to sell shares for cash to fund operations, expansion, and mergers and acquisitions that will dilute the current shareholders;
- it is not anticipated that any dividends will be paid to holders of Common Shares for the foreseeable future; and
- the Company is subject to ongoing reporting requirements under applicable securities laws and exchange policies

In addition, the Company highlights the following risk factors:

Potential Sale of Quebec Facility:

A sale of the Quebec Facility, or a portion thereof, will be subject to a number of conditions including potential financing conditions, and regulatory approvals and there can be no assurances that any such conditions or approvals will be obtained and that the transaction will be completed in a timely manner. There can be no assurances that a sale of the Quebec Facility, or a portion thereof, will be advantageous to the Company or that the Company will be able to receive the fair market value for any disposed assets in connection with such sale and it is possible that completion of such a sale could have a material adverse effect on the financial position of the Company. There can be no assurances that the Québec Facility will ultimately be monetized either by way of a sale or any other form of transaction.

Potential Expansion into the US:

A potential expansion of the business and operations of the Company into the US may require significant regulatory approvals, which could involve potentially high up-front costs, and there can be no assurances that the Company would be able to obtain such approvals after paying such costs. Following an expansion into the US, the Company would be subject to heightened regulatory and financial scrutiny which could lead to increased costs and have a material adverse effect on the financial position of the Company. As at the date of this MD&A, all cannabis-related practices and activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. This may pose a number of potential risks to the Company, including risk associated with banking, financial transactions, prosecution of Company employees and anti-money laundering laws and regulations.

DISCLOSURE CONTROLS AND PROCEDURES

Management is responsible for establishing and maintaining a system of disclosure controls and procedures (“DC&P”) under National Instrument 52-109 to provide reasonable assurance that all material information relating to the Company and its subsidiaries is gathered and reported to senior management on a timely basis so that appropriate decisions can be made regarding public disclosure.

The Chief Executive Officer (“CEO”) and Interim Chief Financial Officer (“Interim CFO”) has designed such disclosure controls and procedures, or caused them to be designed under their supervision, to provide reasonable assurance that material information relating to the Company, including its consolidated subsidiaries, is made known to them by others within those entities, particularly during the period in which the disclosures are being prepared to provide reasonable assurance that information required to be disclosed under securities legislation is recorded, processed, summarized and reported within the time periods specified in the securities legislation.

INTERNAL CONTROL OVER FINANCIAL REPORTING

Management is also responsible for establishing and maintaining adequate internal control over financial reporting (“ICFR”) to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial reports for external purposes in accordance with IFRS.

The CEO and Interim CFO has designed internal control over financial reporting, or caused it to be designed under his supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with IFRS as at March 31, 2021.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There have been no material changes in the Company’s internal control over financial reporting that occurred during the three months ended March 31, 2021, which have materially affected, or are reasonably likely to affect, the Company’s internal controls over financial reporting.

OUTSTANDING SHARE DATA

As of the date of this MD&A, the Company had the following securities issued and outstanding:

Shares	528,070,756
Warrants	159,546,440
Escrowed share units arising from the HemPoland transaction	324,775
Contingent share units arising from the HemPoland transaction	656,784
Restricted share units issued to employees	5,231,873
Stock options	24,288,997

See the Company’s consolidated financial statements for a detailed description of these securities. Each security type is convertible into one Common Share.